Fatigue assessment in Egyptian patients with hepatitis C virus-related chronic liver disease: Single center study

Table 4 Univariate and multivariable regression analysis of risk factors for significant fatigue in chronic liver disease

Variables1	Univariate		Multivariate analysis
	OR (95%CI)	P value	OR (95%CI)	P value
Age (< 45 years/≥ 45 years)	1.67 (0.822-3.44)	0.155
Gender (male/female)	1.35 (0.74-2.3)	0.275
Clinical stage of liver disease (chronic liver disease/compensated/decompensated)	3.4 (1.9-5.9)	0.001	3.3 (1.7-6.6)	0.001
Child score (Child A/Child B and C)	2.2 (1.2-4.1)	0.008
FIB-4 fibrosis classes (low risk/intermediate/high risk)	2.7 (1.6-4.5)	0.001	3.7 (1.7-7.8)	0.001
MELD score (< 15/≥ 15)	11.7 (4.8-28.7)	0.001
Ascites (no/yes)	1.6 (1.2-2.1)	0.001
History of GIT bleeding (no/yes)	1.4 (1.04-1.9)	0.028
History of hepatic encephalopathy (no/yes)	2.09 (1.5-2.87)	0.001
Antiviral treatment (no/yes)	2.7 (1.3-5.5)	0.004
The duration of last dose of antiviral treatment (n = 262) (< 1 year/≥ 1 year)	6.5 (1.5-36.5)	0.033	8.6 (1.27-58.3)	0.027
Antiviral treatment response (n = 262) (response/failure)	2.9 (1.04-8.3)	0.047
HCV infection duration (< 10 years/≥ 10 years)	1.19 (1.12-1.22)	0.003	1.2 (1.13-1.34)	0.001

¹The following variables (age, gender, and previous antiviral treatment, model for end-stage liver disease score and antiviral treatment) response were removed from the final model. Correlated variables also excluded from multivariate model. Hepatitis C virus infection duration categorized according to the median (< 10 years and ≥ 10 years).

OR: Odds ratio; CI: Confidence interval; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; GIT bleeding: Gastrointestinal tract bleeding; FIB-4: Fibrosis-4; MELD: Model for end-stage liver disease.